SUN VALLEY, CA -- (Marketwired) -- 08/12/14 -- MultiCorp International, Inc, (OTC Pink: MCIC) (PINKSHEETS: MCIC) announced today that in a partnership with New World Fuels, LLC, of Ireland, and Principle Risk Solutions out of the U.K. have secured a petroleum storage unit capable of holding 1,000,000 BBL of Jet Fuel in a major shipping port wherein the company now has full control of the storage and sales of Jet Fuel and crude products with full security.
The company issued the following statement, "Through the hard work with our business associates at New World Fuels, LLC and Principle Risk Solutions, MultiCorp has secured a petroleum tank storage facility of 1,000,000 barrel capacity that will be used by the company to control their sales for both current and future contracts for Jet Fuel orders from major companies throughout the world. Through PRS and NWF we're able to completely allow safe transfer of the product at the loading port thereby giving our current clients and potential buyers comfort in knowing all safety measures have been taken to ensure their transactions are smooth and secure," stated, Paul D. Lisenby, CEO of MultiCorp. Mr. Lisenby further adds, "Mr. Rich Corrigan of New World Fuels, LLC has been instrumental in assisting MultiCorp with securing the tank storage facility and will continue to bring his expertise in working closely with MultiCorp to close contracts for sales of fuel and petroleum products. NWF and PRS will also handle all potential rentals of our tanks to other companies that require a safe environment to conduct business. The tanks will remain under MultiCorp and PRS' control in current deals but also create a monthly revenue stream for the company as other buyers look to have a safe and secure storage facility to conduct business."
Mr. Rich Corrigan of New World Fuels, LLC stated, "Working daily with the lads at MultiCorp has allowed our company to have a secure storage facility wherein New World Fuels, Ltd. and MultiCorp can close several contracts that our companies have been working together on over the last few months. We anticipate many contracts to close soon and our continued collaboration will surely benefit both companies in securing additional contracts with major buyers. For buyers of jet fuel and D2 they will now have a safe and secure environment that will surely raise their comfort level in doing business with our companies. We can effectively match up buyers/sellers together to complete transactions in days rather than weeks and utilize the storage tanks to expedite contracts."
Mr. Jason Bailyes of Principal Risk Solutions, stated, "The combination of our partnership ensures we can facilitate transactions in a secure environment. PRS fundamental ability to provide accurate and timely situational security awareness underpins any current or future trade. We are delighted to be working closely with our partners and being able to utilize our experience and proven skill set within this dynamic and exciting marketplace."
For inquiries about purchasing or selling JP 54 and D2 and other petroleum products or fuel storage tank rental, please email Mr. Corrigan at email@example.com Attn: Rich
About New World Fuels, LLC
New World Fuels Ltd. is an Irish based company under the management of Fergus Murphy, Operations Consultant, over 40 years' experience and Rich Corrigan 8 years now within the oil industry, Principal Sales Negotiator. NWF new oil company's horizons based on the foundations of knowledge and experience. NWF team of experienced terminal depot operations personal, shipping and accountancy professional's, founded within the parameters of "service" to our clients. Key character's being honesty, integrity, and trust.
About Principle Risk Solutions
PRS is an ethical supplier of risk mitigation and security related areas of expertise. Internationally accredited and audited to market leading and exacting standards PRS prides itself on facilitating secure and safe environments that enable ongoing business continuity globally. Utilizing the experience of its senior management team and far reaching network PRS provides NGOs, State Actors and commercial clients the ability to effectively mitigate and manage risk.
For more information, please visit their company at https://principalrisksolutions.com/
The medical industry has seen many changes in the past few years, and MultiCorp will continue to operate in this sector. When identifying potential acquisitions in this sector, MultiCorp has a significant advantage over other companies looking for qualified businesses.
Our past work with major healthcare companies such as United Healthcare, Kaiser, and Tenet, to name a few, bodes well for MultiCorp's future. As with any new technology in the medical field, working with the actual companies that can pay for the products/services is the key to generating revenue in this sector.
MultiCorp will look to grow its business now and in the future by identifying breakthroughs in the tele-medicine and tele-health sectors, hospital and clinic construction and operations, healthcare insurance and managed professional groups.
The company has submitted bids throughout the world to build and operate several hospitals, clinics, and other similar medical businesses that offer cutting-edge solutions for countries that have been lagging behind in delivering proper medical care.
The company is also looking to penetrate all facets of the Obamacare solutions for patients and companies that are having a hard time navigating this system. Through alliances with healthcare insurers, medical professionals, and software solution companies, MultiCorp expects to grow in the medical sector for many years to come.
MULTICORP INTERNATIONAL, INC ENGAGES BIOREGENERATIVE SCIENCES, INC and NORTH COUNTY CLINICAL RESEARCH TO DEVELOP CLINICAL TRIAL PROCEDURES ON PATENTED MIGRAINE MEDICINE
Apr 16, 2014
OTC Disclosure & News Service
Sun Valley, CA -
Procedure Report will Set Stage to begin Clinical Trials on Migraine Medication
April 16, 2014 6:00 AM PT
SUN VALLEY, CA - MultiCorp International, Inc, (OTC Pink: MCIC - News) has engaged Dr. Greg Maguire of BioRegenerative Sciences, Inc along with Dr. Valentin Isacescu of North County Clinical Research to work with the company to develop a clear path to begin clinical trials on their patented migraine medicine for eventual approval by the FDA.
The company released the following statement, "We're extremely excited to have such a qualified and experienced group to assist the company in mapping out a clear strategy for the migraine medication to gain approval from the FDA. While we understand this could be a long process, having a group that is so well versed on the proper procedures clinical trials require to gain approval, we feel we've chosen the perfect group to accomplish this portion of the process in the most expeditious manner possible. Once the report is completed in the next four to six weeks, the company will have a clear understanding as to the requirements from the FDA on beginning clinical trials", stated Mr. Paul D. Lisenby, CEO of MultiCorp International, Inc. Mr. Lisenby added, "We feel this medication could become a major player in the $3.2 billion dollar segment of the migraine pharmaceutical vertical."
Dr. Greg Maguire, CEO of BioRegenerative Sciences, Inc, stated, "Our group is very excited to help bring this important new drug candidate for migraines through the FDA 505(b)(2) NDA approval process. Dr Valentin Isacescu added, "Migraine is such a debilitating disorder for so many patients and a tremendous need exists for a medication to prevent and control this malady."
About MultiCorp International, Inc.
MultiCorp International, Inc is a diverse company that operates in various business sectors that show true growth potential. The company builds on its executives experience in property development, constructions, medical, hospitality, agribusiness, commodities such as oil and gas, and entertainment. The company looks to expand through acquisitions of solid business models and management that have the potential to grow exponentially. The company will have additional subsidiaries that will eventually grow into being their own public entity, be sold, or continue to operate within MultiCorp. For further information please contact them at firstname.lastname@example.org
About BioRegenerative Sciences, Inc.
BioRegenerative Sciences, Inc. is a privately held corporation headquartered in San Diego, CA and currently has fifteen patent pending products on the market and is further developing a portfolio of therapeutic and cosmeceutical products and services based on BRS's core stem cell-based S2RM(R) Technology. For more information, please email: email@example.com, or call BRS at 858. 521.9203.
About North County Clinical Research
North County Clinical Research (NCCR) is a dedicated clinical research site located in the North County of San Diego. We specialize in central nervous system (CNS) indications, some medical indications, drug dependence, alcohol dependence, nicotine dependence, sleep disorders, and chronic pain clinical trials. We are comprised of physicians and research staff with over 20 years of combined experience conducting phase II through phase IV clinical trials. Our site is affiliated with Aurora Behavioral Health Care which provides excellent opportunities for recruitment and inpatient clinical trials.
For more information, please visit their website at http://www.nccresearch.com/
Multicorp International, Inc Acquires 70% Ownership in Patented Migraine Headache Medication
|Multicorp International, Inc Acquires 70% Ownership in Patented Migraine Headache Medication |
Company Seeking Clinical Trial Partner to Begin Testing in First Quarter of 2014
SUN VALLEY, CA--(Marketwired - Dec 17, 2013) - MultiCorp International, Inc, (OTC Pink: MCIC) has acquired a 70% stake in a patented migraine medication. The company released the following statement:
"MultiCorp International, Inc has acquired a 70% ownership in a patented migraine medicine that has shown to aid in the symptoms of migraine headaches. According to www.migraine.com in the U.S. alone more than 37 million people suffer from migraines and globally over 330 million people have migraines on a constant basis. The medication was developed by a physician that MultiCorp will work closely with in order to gain FDA approval for the medication. The company plans to begin clinical trials in the first quarter of 2014 and hope to have the medication to market as soon as possible. The information on the patent can be found at http://www.faqs.org/patents/app/20090018205. Under the terms of the agreement, MultiCorp will have full authority to oversee the clinical trials of the product, marketing and selling of the medication, as well the overall business of getting the product to market as quickly as possible and retaining a 70% interest in the product. With the average cost of $145 per month in medication for migraine sufferers, the market for this product is exponential here in the U.S. and globally."
For companies wishing to assist MultiCorp in clinical trials, please email us at firstname.lastname@example.org
About MultiCorp International
MultiCorp International, Inc is a diverse company that operates in various business sectors that show true growth potential. The company builds on its executives experience in property development, constructions, medical, and hospitality as well as commodities such as oil and gas, and entertainment.
MultiCorp seeks out and acquires companies in several targeted business fields that have strong potential, seasoned management experience, and show true potential for exponential growth.
While our process may seem simple to some - look for and acquire companies in growth sectors - our standards are set high. A complete due diligence package must be met before any consideration is made to move forward. If, at any time, any component of our criteria is not met, that potential business will not be considered to become part of MultiCorp International, Inc.
MultiCorp will continue to build and grow in the future. Our expansion will be global in nature and the company continues to look at projects/companies throughout the world. The vision of management for MultiCorp is to diversify into many fields wherein management's expertise along with our strategic partners experience will raise the company's bottom line profitability
Paul D. Lisenby - Chairman and CEO
Mr. Lisenby has been in the capital markets since 1996. Paul managed a $100 million fund that invested in small cap companies, large indexes as well as private equity funding. In addition, Paul was responsible for negotiating several acquisitions to include a software company valued at $186 million dollars as well as several other companies that brought in over $200 million in revenue throughout his executive career. Mr. Lisenby has been at the helm of MultiCorp since its inception in 2007 as XTend Medical. Mr. Lisenby holds a BA and MBA.
Ben Friedman - President
Mr. Friedman has worked in the medical and pharmacology business for over 35 years. A licensed pharmacist, Mr. Friedman has overseen developing several proprietary prescription compounds and several OTC medications throughout his career. In addition, Ben owned hotels and other properties he's developed. Ben also has been working in the capital markets since 2005 wherein his financial acumen has helped companies raise in excess of $15 million in private funding. Mr. Friedman currently holds a BA in business and is currently licensed to practice pharmacy in California and hold his board certification in pharmacology
AS info DE. Dept. of Corp.
24/7 Phone: 302-739-3073, press #8 file number 3866564
Note: Web site does not give the AS. Must call, automated 24/7, or during business hours if one wishes to speak in person.
MultiCorp International, Inc
10771 Sherman Way
Sun Valley, CA 91352
Phone: (818) 255-2476
Fax: (818) 255-2122
Signature Stock Transfer, Inc.
2632 Coachlight Ct.
Email - email@example.com
This board is for discussing XMDC.
Information posted either positive or negative is accepted.
Personal attacks, repetitive, off topic posts or outright flame baiting posts are not accepted.
Posts that respond to PM (One way messages) are not allowed. Vulgarity is not acceptable. Violation of ones privacy is not acceptable.
Posts in violation of the rules will be deleted. Repeat offenders will be reported to the admins of IHUB.
Rules of the board per IHUB:
As of 06/18/08: 28,437,031 shares outstanding: 21,403,469 shares free trading: 7,033,562 shares restricted
As of 07/01/08: 28,437,031 shares outstanding: 21,403,469 shares free trading: 7,033,562 shares restricted
As of 07/03/08: 28,437,031 shares outstanding: 21,403,469 shares free trading: 7,033,562 shares restricted
As of 07/14/08: 28,437,031 shares outstanding: 21,403,469 shares free trading: 7,033,562 shares restricted
As of 07/16/08: 31,237,031 shares outstanding: 24,203,809 shares free trading: 7,033,562 shares restricted
As of 07/23/08: 36,737,031 shares outstanding: 30,057,796 shares free trading: 6,679,235 shares restricted; 150,000,000 shares Authorized.
As of 08/06/08: 36,737,031 shares outstanding: 30,057,796 shares free trading: 6,679,235 shares restricted; 150,000,000 shares Authorized.
As of 08/13/08: 36,737,031 shares outstanding: 30,057,796 shares free trading: 6,679,235 shares restricted; 150,000,000 shares Authorized.
As of 08/22/08: 86,737,031 shares outstanding: 80,057,796 shares free trading: 6,679,235 shares restricted; 1,000,000,000 shares Authorized.
As of 08/25/08: 101,737,031 shares outstanding: 95,057,796 shares free trading: 6,679,235 shares restricted; 1,000,000,000 shares Authorized.
As of 09/02/08: 245,737,031 shares outstanding: 239,489,809 shares free trading: 6,247,222 shares restricted; 1,000,000,000 shares Authorized.
As of 07/21/09: 256,737,031 shares outstanding: 239,065,599 shares free trading: 17,671,432 shares restricted; 1,000,000,000 shares Authorized.
As of 09/22/09: 256,737,031 shares outstanding: 239,065,599 shares free trading: 17,671,432 shares restricted; 1,000,000,000 shares Authorized.
As of 10/05/09: 616,737,031 shares outstanding: 299,065,600 shares free trading: 317,671,431 shares restricted; 1,000,000,000 shares Authorized.
As of 10/05/09: 616,737,031 shares outstanding: 299,065,600 shares free trading: 317,671,431 shares restricted; 1,000,000,000 shares Authorized.
As of 10/27/09: 636,737,031 shares outstanding: 319,497,611 shares free trading: 317,671,431 shares restricted; 1,000,000,000 shares Authorized.
As of 11/04/09: 649,737,031 shares outstanding: 332,065,600 shares free trading: 317,671,431 shares restricted; 1,000,000,000 shares Authorized.
As of 11/09/09: 766,487,031 shares outstanding: 351,681,600 shares free trading: 414,805,431 shares restricted; 1,000,000,000 shares Authorized.
As of 11/18/09: 770,487,031 shares outstanding: 355,681,600 shares free trading: 414,805,431 shares restricted; 1,000,000,000 shares Authorized.
As of 12/03/09: 783,137,031 shares outstanding: 370,891,600 shares free trading: 412,245,431 shares restricted; 1,000,000,000 shares Authorized.
As of 12/10/09: 986,490,863 shares outstanding: 378,391,600 shares free trading: 608,099,263 shares restricted; 1,000,000,000 shares Authorized.
As of 02/01/10: 986,490,863 shares outstanding: 390,766,744 shares free trading: 595,724,119 shares restricted; 1,000,000,000 shares Authorized.
As of 02/12/10: 986,490,863 shares outstanding: 390,766,744 shares free trading: 595,724,119 shares restricted; 1,000,000,000 shares Authorized.
As of 10/17/10: 986,490,863 shares outstanding: 390,766,744 shares free trading: 595,724,119 shares restricted; 1,750,000,000 shares Authorized.
As of 12/31/11 1,384,887,031 shares outstanding:462,855,646 shares free trading: 922,031,385 shares restricted:1,750,000,000 shares Authorized.
As of 08/30/12 984,887,031 shares outstanding: : 462,885,646 Free Trading : 1,750,000,000 shares Authorized.
SHAREHOLDERS' EQUITY, Per Company Balanced sheet
As of Sept 30, 2012 the company has 1,392,887,031
shares of common stock issued and outstanding.